BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 35132238)

  • 1. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.
    Flach S; Howarth K; Hackinger S; Pipinikas C; Ellis P; McLay K; Marsico G; Forshew T; Walz C; Reichel CA; Gires O; Canis M; Baumeister P
    Br J Cancer; 2022 May; 126(8):1186-1195. PubMed ID: 35132238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
    Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
    Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
    Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
    Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.
    Huang X; Duijf PHG; Sriram S; Perera G; Vasani S; Kenny L; Leo P; Punyadeera C
    J Biomed Sci; 2023 Aug; 30(1):65. PubMed ID: 37559138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma.
    Kogo R; Manako T; Iwaya T; Nishizuka S; Hiraki H; Sasaki Y; Idogawa M; Tokino T; Koide A; Komune N; Yasumatsu R; Nakagawa T
    Cancer Med; 2022 Nov; 11(21):3960-3968. PubMed ID: 35352507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck.
    Sanz-Garcia E; Zou J; Avery L; Spreafico A; Waldron J; Goldstein D; Hansen A; Cho BCJ; de Almeida J; Hope A; Hosni A; Hahn E; Perez-Ordonez B; Zhao Z; Smith C; Zheng Y; Singaravelan N; Bratman SV; Siu LL
    Cell Death Differ; 2024 Apr; 31(4):460-468. PubMed ID: 38409276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy.
    Hilke FJ; Muyas F; Admard J; Kootz B; Nann D; Welz S; Rieß O; Zips D; Ossowski S; Schroeder C; Clasen K
    Radiother Oncol; 2020 Oct; 151():182-189. PubMed ID: 32687856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison between mutational profiles in tumour tissue DNA and circulating tumour DNA in head and neck squamous cell carcinoma - A systematic review.
    Huang X; Leo P; Jones L; Duijf PHG; Hartel G; Kenny L; Vasani S; Punyadeera C
    Mutat Res Rev Mutat Res; 2024; 793():108477. PubMed ID: 37977279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients.
    Taylor K; Zou J; Magalhaes M; Oliva M; Spreafico A; Hansen AR; McDade SS; Coyle VM; Lawler M; Elimova E; Bratman SV; Siu LL
    Eur J Cancer; 2023 Jul; 188():29-38. PubMed ID: 37182343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutated
    Kampel L; Feldstein S; Tsuriel S; Hannes V; Carmel Neiderman NN; Horowitz G; Warshavsky A; Leider-Trejo L; Hershkovitz D; Muhanna N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma.
    Chikuie N; Urabe Y; Ueda T; Hamamoto T; Taruya T; Kono T; Yumii K; Takeno S
    Sci Rep; 2022 Jun; 12(1):9316. PubMed ID: 35661138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
    Burgener JM; Zou J; Zhao Z; Zheng Y; Shen SY; Huang SH; Keshavarzi S; Xu W; Liu FF; Liu G; Waldron JN; Weinreb I; Spreafico A; Siu LL; de Almeida JR; Goldstein DP; Hoffman MM; De Carvalho DD; Bratman SV
    Clin Cancer Res; 2021 Aug; 27(15):4230-4244. PubMed ID: 34158359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
    Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
    Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
    van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
    BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour DNA detects somatic variants contributing to spatial and temporal intra-tumoural heterogeneity in head and neck squamous cell carcinoma.
    Payne KFB; Brotherwood P; Suriyanarayanan H; Brooks JM; Batis N; Beggs AD; Gendoo DMA; Mehanna H; Nankivell P
    Front Oncol; 2024; 14():1374816. PubMed ID: 38846976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review.
    Pall AH; Jakobsen KK; Grønhøj C; von Buchwald C
    Acta Oncol; 2020 Jul; 59(7):845-850. PubMed ID: 32223478
    [No Abstract]   [Full Text] [Related]  

  • 17. Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer.
    Muhanna N; Di Grappa MA; Chan HHL; Khan T; Jin CS; Zheng Y; Irish JC; Bratman SV
    Sci Rep; 2017 Dec; 7(1):16723. PubMed ID: 29196748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.
    Honoré N; van der Elst A; Dietz A; van Marcke C; Helaers R; Mendola A; Dahou H; Marbaix E; Poncin R; Seront E; Schmitz S; Limaye N; Galot R; Machiels JP
    Eur J Cancer; 2023 Dec; 195():113372. PubMed ID: 37913682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN).
    Galot R; Machiels JH
    Cancer Treat Rev; 2020 Apr; 85():101992. PubMed ID: 32092618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.